Conferences - Results from #280

ASCO GU 2025: Real-World Time on Treatment with First-Line Enfortumab Vedotin and Pembrolizumab After U.S. FDA Approval for Advanced Urothelial Cancer February 15, 2025

ASCO GU 2025: Clinical Efficacy of Enfortumab Vedotin + Pembrolizumab in Locally Advanced or Metastatic Urothelial Carcinoma: A Real-World Retrospective Study February 15, 2025

ASCO GU 2025: Evolution of ctDNA Detection with Next Generation Technology February 15, 2025

ASCO GU 2025: Clinically Advanced Urothelial Bladder Cancer in Young Onset Bladder Cancer (YOUC) Patients: A Genomic Landscape Study February 15, 2025

ASCO GU 2025: A Phase 2 Trial of Risk Enabled Therapy After Neoadjuvant Chemo-Immunotherapy for Muscle-Invasive Bladder Cancer (RETAIN-2) February 15, 2025

ASCO GU 2025: A Phase 1/2 Trial of Durvalumab plus Intravesical Gemcitabine and Docetaxel in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Patients (HCRN GU16-243: ADAPT-BLADDER Cohort 4) February 15, 2025

ASCO GU 2025: Case-Based Session: Non-Muscle Invasive Bladder Cancer: Exploring Therapies Beyond Bacillus Calmette-Guérin February 15, 2025

ASCO GU 2025: A First-in-Human Phase 1 Study of LY3866288 (LOXO-435), a Potent, Highly Isoform-Selective FGFR3 Inhibitor (FGFR3i) in Advanced Solid Tumors with FGFR3 Alterations: Initial Results from FORAGER-1 February 15, 2025

ASCO GU 2025: Molecular Subtypes, NECTIN4/HER2 Expression, and Clinical Outcomes in Patients with Advanced Urothelial Carcinoma or Muscle Invasive Bladder Cancer: Exploratory Analyses from JAVELIN Bladder 100 and the Tempus Databases February 15, 2025

ASCO GU 2025: Beneath the Surface: Unleashing the Potential of ctDNA across the Spectrum of Urothelial Carcinoma February 15, 2025

ASCO GU 2025: Updated Long-Term Follow-up from a Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients with High-Grade Upper Tract Urothelial Carcinoma. February 15, 2025

ASCO GU 2025: Datopotamab Deruxtecan (Dato-DXd) in Locally Advanced/metastatic Urothelial Cancer: Updated Results from the Phase 1 TROPION PanTumor01 Study February 15, 2025

ASCO GU 2025: EV-302: Updated Analysis from the Phase 3 Global Study of Enfortumab Vedotin in Combination with Pembrolizumab (EV+P) vs Chemotherapy (Chemo) in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) February 15, 2025

ASCO GU 2025: Impact of Tumor Burden or Focality in Recurrent Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer on Response to Treatment with UGN-102: A Substudy of the Phase 3 ENVISION Trial February 15, 2025

ASCO GU 2025: Treatment of Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer With UGN-102: Results of the Phase 3 ATLAS and ENVISION Studies February 15, 2025

ASCO GU 2025: Discussant: Advancements in Urothelial Cancer Perioperative Therapy February 15, 2025

ASCO GU 2025: Discussant: Adjuvant Immunotherapy in High Risk Muscle Invasive Bladder Cancer February 15, 2025

ASCO GU 2025: Optyx Study: Clinical Characteristics and Preferences for Initiating Relugolix in a Cohort of US Patients in Real-World Care Settings February 15, 2025

ASCO GU 2025: Treatment sequence and overall survival in patients with metastatic urothelial cancer: An observational, multicenter, real-life STATES-Bladder study. February 15, 2025

ASCO GU 2025: Kidney-Sparing Approach for Selected Localized High-Risk Upper Tract Urothelial Carcinoma: A Pilot Study Combining Endoscopic Thulium Laser Ablation With Perioperative Disitamab Vedotin and Immune Checkpoint Inhibitors February 15, 2025

Page 15 of 616